A site-specific genomic integration strategy for sustained expression of glucagon-like peptide-1 in mouse muscle for controlling energy homeostasis

Biochemical and Biophysical Research Communications

Volumn 403, Issue 2, 2010, Pages 172-177

  Liu, Rui ^a,b   Li, Yiming ^a   Hu, Renmin ^a   Jin, Tianru ^c   Deng, Shanshan ^d   Liang, Wang ^d   Zhang, Nina ^b   Chen, Jinzhong ^e   Prud'homme, Gerald J ^b   Jia, William W ^e,f   Ma, Duan ^d   Wang, Qinghua ^a,b,c  

^a FUDAN UNIVERSITY   (China)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d FUDAN UNIVERSITY   (China)

^e FUDAN UNIVERSITY   (China)

^f UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

AAVS1; Diabetes; Genome integration; GLP 1; High fat diet; Obesity; RBE; Rep78

Indexed keywords

GLUCAGON LIKE PEPTIDE 1; IMMUNOGLOBULIN FRAGMENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHROMOSOME 19; CONTROLLED STUDY; DNA INTEGRATION; DOT HYBRIDIZATION; ENERGY METABOLISM; GENE CASSETTE; GENE LOCUS; GENE THERAPY; GENE TRANSFER; HUMAN; IMMUNOHISTOCHEMISTRY; LIPID DIET; MOUSE; MUSCLE; NONHUMAN; OUTCOME ASSESSMENT; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SOUTHERN BLOTTING; STABLE EXPRESSION; WEIGHT GAIN;

ANIMALS; CHROMOSOMES, HUMAN, PAIR 19; DNA-BINDING PROTEINS; ENERGY METABOLISM; GENE THERAPY; GENETIC ENGINEERING; GENETIC LOCI; GENOME; GLUCAGON-LIKE PEPTIDE 1; HOMEOSTASIS; HUMANS; MICE; MICE, TRANSGENIC; MUSCLE, SKELETAL; PLASMIDS; RECOMBINATION, GENETIC; VIRAL PROTEINS; WEIGHT GAIN;

MUS; MUS MUSCULUS;

EID: 78649929753     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2010.10.131     Document Type: Article

References (36)

1. Baggio L.L., Drucker D.J. Harnessing the therapeutic potential of glucagon-like peptide-1: a critical review. Treat. Endocrinol. 2002, 1:117-125.
2. Schirra J., Wank U., Arnold R., Goke B., Katschinski M. Effects of glucagon-like peptide-1(7-36)amide on motility and sensation of the proximal stomach in humans. Gut 2002, 50:341-348.
3. Deacon C.F., Johnsen A.H., Holst J.J. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J. Clin. Endocrinol. Metab. 1995, 80:952-957.
4. Buse J.B., Drucker D.J., Taylor K.L., Kim T., Walsh B., Hu H., Wilhelm K., Trautmann M., Shen L.Z., Porter L.E. Duration-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks. Diabetes Care 2010, 22:56-98.
5. Vilsboll T., Zdravkovic M., Le-Thi T., Krarup T., Schmitz O., Courreges J.P., Verhoeven R., Buganova I., Madsbad S. Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care 2007, 30:1608-1610.
6. Soltani N., Kumar M., Glinka Y., Prud'homme G.J., Wang Q. In vivo expression of GLP-1/IgG-Fc fusion protein enhances beta-cell mass and protects against streptozotocin-induced diabetes. Gene Ther. 2007, 14:981-988.
7. Kumar M., Hunag Y., Glinka Y., Prud'homme G.J., Wang Q. Gene therapy of diabetes using a novel GLP-1/IgG1-Fc fusion construct normalizes glucose levels in db/db mice. Gene Ther. 2007, 14:162-172.
8. Lee Y.S., Shin S., Shigihara T., Hahm E., Liu M.J., Han J., Yoon J.W., Jun H.S. Glucagon-like peptide-1 gene therapy in obese diabetic mice results in long-term cure of diabetes by improving insulin sensitivity and reducing hepatic gluconeogenesis. Diabetes 2007, 56:1671-1679.
9. Riedel M.J., Gaddy D.F., Asadi A., Robbins P.D., Kieffer T.J. DsAAV8-mediated expression of glucagon-like peptide-1 in pancreatic beta-cells ameliorates streptozotocin-induced diabetes. Gene Ther. 2010, 17:171-180.
10. Kotin R.M., Linden R.M., Berns K.I. Characterization of a preferred site on human chromosome 19q for integration of adeno-associated virus DNA by non-homologous recombination. EMBO J. 1992, 11:5071-5078.
11. Linden R.M., Winocour E., Berns K.I. The recombination signals for adeno-associated virus sitespecific integration. Proc. Natl. Acad. Sci. USA 1996, 93:7966-7972.
12. Philpott N.J., Gomos J., Berns K.I., Falck-Pedersen E. A p5 integration efficiency element mediates Rep-dependent integration into AAVS1 at chromosome 19. Proc. Natl. Acad. Sci. USA 2002, 99:12381-12385.
13. Xu Z.X., Chen J.Z., Yue Y.B., Zhang J.Q., Li Z.H., Feng D.M., Ruan Z.C., Tian L., Xue J.L., Wang Q.J., Jia W. A 16-bp RBE element mediated Rep-dependent site-specific integration in AAVS1 transgenic mice for expression of hFIX. Gene Ther. 2009, 16:589-595.
14. Feng D., Chen J., Yue Y., Zhu H., Xue J., Jia W.W. A 16bp Rep binding element is sufficient for mediating Rep-dependent integration into AAVS1. J. Mol. Biol. 2006, 358:38-45.
15. Q. Wang, K. Chen, R. Liu, R. Liu, Z. Fang, S. Gupta, N. Zhang, G.J. Prud'homme, Q. Wang, Novel GLP-1 fusion chimera as potent long acting GLP-1 receptor agonist, PLoS ONE 5[9], (2010) e12734.
16. Bakowska J.C., Di Maria M.V., Camp S.M., Wang Y., Allen P.D., Breakefield X.O. Targeted transgene integration into transgenic mouse fibroblasts carrying the full-length human AAVS1 locus mediated by HSV/AAV rep(+) hybrid amplicon vector. Gene Ther. 2003, 10:1691-1702.
17. Wang Q., Brubaker P.L. Glucagon-like peptide-1 treatment delays the onset of diabetes in 8 week-old db/db mice. Diabetologia 2002, 45:1263-1273.
18. Goncalves M.A., van Nierop G.P., Tijssen M.R., Lefesvre P., Knaan-Shanzer S., d V van I., van Bekkum D.W., Valerio D., de Vries A.A. Transfer of the full-length dystrophin-coding sequence into muscle cells by a dual high-capacity hybrid viral vector with site-specific integration ability. J. Virol. 2005, 79:3146-3162.
19. Donsante A., Miller D.G., Li Y., Vogler C., Brunt E.M., Russell D.W., Sands M.S. AAV vector integration sites in mouse hepatocellular carcinoma. Science 2007, 317:477.
20. Prud'homme G.J., Draghia-Akli R., Wang Q. Plasmid-based gene therapy of diabetes mellitus. Gene Ther. 2007, 14:553-564.
21. McCormack M.P., Rabbitts T.H. Activation of the T-cell oncogene LMO2 after gene therapy for X-linked severe combined immunodeficiency. N. Engl. J. Med. 2004, 350:913-922.
22. Recchia A., Perani L., Sartori D., Olgiati C., Mavilio F. Site-specific integration of functional transgenes into the human genome by adeno/AAV hybrid vectors. Mol. Ther. 2004, 10:660-670.
23. Rizzuto G., Gorgoni B., Cappelletti M., Lazzaro D., Gloaguen I., Poli V., Sgura A., Cimini D., Ciliberto G., Cortese R., Fattori E., La M.N. Development of animal models for adeno-associated virus site-specific integration. J. Virol. 1999, 73:2517-2526.
24. Flint A., Raben A., Rehfeld J.F., Holst J.J., Astrup A. The effect of glucagon-like peptide-1 on energy expenditure and substrate metabolism in humans. Int. J. Obes. Relat Metab Disord. 2000, 24:288-298.
25. Baggio L.L., Huang Q., Brown T.J., Drucker D.J. A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis. Diabetes 2004, 53:2492-2500.
26. Riediger T., Eisele N., Scheel C., Lutz T.A. Effects of glucagon-like peptide 1 and oxyntomodulin on neuronal activity of ghrelin-sensitive neurons in the hypothalamic arcuate nucleus. Am. J. Physiol Regul. Integr. Comp Physiol 2010, 298:R1061-R1067.
27. Enriori P.J., Evans A.E., Sinnayah P., Jobst E.E., Tonelli-Lemos L., Billes S.K., Glavas M.M., Grayson B.E., Perello M., Nillni E.A., Grove K.L., Cowley M.A. Diet-induced obesity causes severe but reversible leptin resistance in arcuate melanocortin neurons. Cell Metab. 2007, 5:181-194.
28. Perreault M., Istrate N., Wang L., Nichols A.J., Tozzo E., Stricker-Krongrad A. Resistance to the orexigenic effect of ghrelin in dietary-induced obesity in mice. reversal upon weight loss. Int. J. Obes. Relat Metab Disord. 2004, 28:879-885.
29. Klok M.D., Jakobsdottir S., Drent M.L. The role of leptin and ghrelin in the regulation of food intake and body weight in humans: a review. Obes. Rev. 2007, 8:21-34.
30. Gedulin B.R., Nikoulina S.E., Smith P.A., Gedulin G., Nielsen L.L., Baron A.D., Parkes D.G., Young A.A. Exenatide (exendin-4) improves insulin sensitivity and {beta}-cell mass in insulin-resistant obese fa/fa Zucker rats independent of glycemia and body weight. Endocrinology 2005, 146:2069-2076.
31. Kaminski J.M., Huber M.R., Summers J.B., Ward M.B. Design of a nonviral vector for site-selective, efficient integration into the human genome. FASEB J. 2002, 16:1242-1247.
32. Huser D., Weger S., Heilbronn R. Kinetics and frequency of adeno-associated virus site-specific integration into human chromosome 19 monitored by quantitative real-time PCR. J. Virol. 2002, 76:7554-7559.
33. Wang Z., Troilo P.J., Wang X., Griffiths T.G., Pacchione S.J., Barnum A.B., Harper L.B., Pauley C.J., Niu Z., Denisova L., Follmer T.T., Rizzuto G., Ciliberto G., Fattori E., Monica N.L., Manam S., Ledwith B.J. Detection of integration of plasmid DNA into host genomic DNA following intramuscular injection and electroporation. Gene Ther. 2004, 11:711-721.
34. Saudan P., Vlach J., Beard P. Inhibition of S-phase progression by adeno-associated virus Rep78 protein is mediated by hypophosphorylated pRb. EMBO J. 2000, 19:4351-4361.
35. Urabe M., Kogure K., Kume A., Sato Y., Tobita K., Ozawa K. Positive and negative effects of adeno-associated virus Rep on AAVS1-targeted integration. J. Gen. Virol. 2003, 84:2127-2132.
36. Bell P., Wang L., Lebherz C., Flieder D.B., Bove M.S., Wu D., Gao G.P., Wilson J.M., Wivel N.A. No evidence for tumorigenesis of AAV vectors in a large-scale study in mice. Mol. Ther. 2005, 12:299-306.